Celgene will pay Mylan $62 million to resolve a lawsuit alleging that it improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.
Mylan disclosed the settlement in a filing with the U.S. Securities and Exchange Commission, days after Celgene agreed to pay $55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.
Read the Reuters report